Verastem Oncology (Nasdaq: VSTM), the Boston-based developer of targeted cancer medicines, announced on October 14, 2026, that its investigational oral KRAS G12D inhibitor VS-7375 achieved a 50% confirmed objective response rate among eight patients receiving second-line treatment for metastatic pancreatic ductal adenocarcinoma. Across 22 previously treated pancreatic cancer patients receiving the selected 900 mg once-daily dose, the confirmed response rate was 41%, with two complete responses observed, one confirmed and one awaiting confirmation. The findings come from the ongoing TARGET-D 101 Phase 1/2 study and represent an important early clinical signal in a disease where effective treatments remain limited.
The company also reported a 43% confirmed response rate among 23 previously treated patients with KRAS G12D-mutated non-small cell lung cancer receiving 600 mg daily. In metastatic colorectal cancer, two of six heavily pretreated patients receiving VS-7375 at 900 mg alongside anti-EGFR treatment experienced objective responses, although only one was confirmed. These results support the investigation of VS-7375 across multiple malignancies driven by the same KRAS mutation, but they come from small, nonrandomized treatment cohorts.
Verastem has reached agreement with the FDA on the design of a planned first-line Phase 3 study in metastatic pancreatic cancer, with trial opening targeted before the end of 2026. The three-arm investigation will compare two VS-7375-containing combinations against standard chemotherapy options, examining progression-free survival and objective response as dual primary endpoints. The company is also advancing separate Phase 2 programmes in pancreatic, lung and colorectal cancers.
Alongside the clinical announcement, Verastem priced a public offering expected to generate approximately $250 million in gross proceeds to support continued development and other corporate requirements. The simultaneous financing and clinical update underscore the capital needed to investigate VS-7375 in larger populations. However, the early response rates do not establish an improvement in overall survival, and the proposed Phase 3 programme remains subject to successful execution and subsequent regulatory assessment.
Why is KRAS G12D a major therapeutic target in pancreatic cancer?
KRAS is a signaling protein involved in regulating cell growth and survival. Mutations that cause the protein to remain abnormally active can promote cancer development and continued tumor proliferation. Different KRAS mutations affect different parts of the protein, creating opportunities and challenges for developing targeted treatments.
KRAS G12D is especially important in pancreatic ductal adenocarcinoma, where Verastem estimates that it occurs in approximately 40% of tumors. The mutation also appears in colorectal, lung and other cancers, although its frequency varies substantially between malignancies. This distribution creates a potentially broad development opportunity for medicines capable of selectively inhibiting the altered protein.
Targeting KRAS has historically been challenging because the protein’s structure and binding properties complicated conventional small-molecule drug discovery. The development of inhibitors directed against KRAS G12C demonstrated that selected mutations can be targeted effectively. However, medicines developed for G12C do not automatically inhibit G12D because the mutations have different chemical characteristics.
No FDA-approved treatment specifically targeting KRAS G12D was identified in Verastem’s October disclosure. Patients with KRAS G12D-mutated pancreatic cancer therefore generally rely on established chemotherapy and other treatments appropriate to their disease. A targeted oral medicine could become an important addition if clinical trials demonstrate an acceptable benefit-risk profile.
The presence of the mutation alone does not guarantee sensitivity to treatment. Cancers can activate alternative signaling pathways, develop resistance or differ in their dependence on KRAS activity. VS-7375 must therefore demonstrate both molecular target engagement and clinically meaningful tumor control.
What does a 50% response rate mean when only eight second-line patients were evaluated?
The headline result involves four confirmed objective responses among eight patients receiving second-line therapy for metastatic pancreatic ductal adenocarcinoma. These patients were treated with VS-7375 at 900 mg orally once daily after previous systemic treatment. The observed response rate of 50% is encouraging, but its interpretation depends heavily on the small denominator.
Each patient represents 12.5 percentage points of the eight-person cohort. A difference of only one responding patient would therefore change the reported response rate substantially. The result provides an early estimate rather than a precise measure of the treatment’s expected effectiveness across a wider population.
The more informative broader analysis includes 22 patients who had received at least one previous line of therapy. Nine achieved confirmed objective responses, producing a rate of approximately 41%. This population included the eight second-line patients and 14 patients receiving treatment in the third or fourth line.
Among the 14 later-line patients, five achieved confirmed responses, corresponding to approximately 36%. These findings suggest that antitumor activity was observed across different prior-treatment settings. However, differences in patient characteristics and treatment history limit direct comparisons between the subgroups.
Two patients in the 22-person modified intention-to-treat analysis were not evaluable for tumor response. One died from coronary artery disease and stroke, while another withdrew consent before the first disease assessment and subsequently died. Verastem stated that neither death was related to VS-7375, and both patients remained in the analysis denominator.
Including such patients is important for interpreting the response estimate because it avoids restricting the calculation exclusively to participants who completed tumor assessment. Nevertheless, the dataset remains early, with median follow-up of 6.4 months.
How significant are the complete responses and six-month disease-control findings?
Verastem reported two complete responses among the 22 pancreatic cancer patients receiving 900 mg daily. One had been confirmed through the relevant assessment process, while the second remained unconfirmed at the October 7 data cutoff. The unconfirmed observation should not be counted as an additional confirmed complete response.
Complete response generally means that detectable target disease has disappeared according to the applicable response criteria. It is a particularly notable observation in previously treated metastatic pancreatic cancer, where deep tumor regression can be difficult to achieve. However, a complete imaging response does not necessarily establish elimination of every cancer cell or permanent remission.
The company reported an overall disease-control rate of 86% in the 22-patient group. Disease control generally combines complete response, partial response and stable disease according to prespecified criteria. Its interpretation depends on the durability of these outcomes and how long patients remained progression-free.
Verastem also disclosed a six-month landmark progression-free survival rate of 67% and an overall survival rate of 80%. Sixteen of the 22 patients remained on treatment at the data cutoff. These observations suggest that several responses and periods of disease control were ongoing, but the survival estimates remain immature.
Median follow-up was only 6.4 months, with substantial variation between patients. Consequently, the six-month rates cannot establish a durable survival advantage over standard treatment. A randomized clinical comparison will be necessary to determine whether adding VS-7375 improves outcomes that matter to patients.
What do the circulating tumor DNA results reveal about KRAS inhibition?
One of the more distinctive findings concerns circulating tumor DNA, or ctDNA, containing the KRAS G12D mutation. Tumor-associated DNA fragments can sometimes be detected in blood, offering a way to measure changes in molecular disease burden during treatment. This provides a complementary assessment to conventional imaging.
Among 12 evaluable pancreatic cancer patients with detectable KRAS G12D ctDNA at baseline, all 12 achieved at least a 50% reduction in mutant variant allele frequency by the beginning of the third treatment cycle. Eleven patients, representing approximately 92%, achieved reductions of at least 90%. Seven patients, or about 58%, reached undetectable levels of the relevant ctDNA signal.
The findings provide evidence of substantial molecular activity in the selected evaluable patients. Verastem also reported that 15 of 17 pancreatic cancer patients with elevated baseline CA19-9 experienced a reduction exceeding 50% in that tumor marker. These observations support the interpretation that the treatment is affecting biological processes associated with cancer activity.
However, the ctDNA and CA19-9 analyses involve different selected populations. Their percentages cannot be combined to calculate a single treatment response rate. Patients without detectable baseline ctDNA or elevated CA19-9 were not included in the respective analyses.
A decline in ctDNA also does not establish that the cancer has been eradicated. Detection depends on assay sensitivity, sample characteristics and the amount of tumor material released into circulation. Molecular changes may provide early evidence of activity, but their relationship with progression-free and overall survival must be established in larger studies.
Why has Verastem selected 900 mg as the preferred monotherapy dose?
Verastem compared clinical findings across several daily dose levels during TARGET-D 101. The company reported that 900 mg produced deeper tumor reductions and higher confirmed response rates than the 600 mg regimen in the evaluated pancreatic cancer populations. Pharmacokinetic analysis also showed greater drug exposure at the higher dose.
In the 600 mg pancreatic cancer group, eight of 27 patients achieved an objective response, but only four had confirmed responses at the cutoff. Eleven remained on treatment. These figures provide context for management’s decision to advance 900 mg, although the groups were not randomized against one another.
The company reported that the safety profiles of 600 mg and 900 mg were generally similar in the available data. In the 48-patient safety population receiving 900 mg monotherapy across tumor types, treatment discontinuation due to adverse events was approximately 2%. Grade 3 treatment-related adverse events occurred in 10% of patients.
Gastrointestinal events, including nausea, vomiting and diarrhea, were the most frequently described treatment-related effects. Verastem reported only one Grade 3 gastrointestinal event at the 900 mg dose in the evaluated safety group, with supportive treatment used to manage symptoms. It also reported no clinically meaningful cytopenias or liver function abnormalities during the period assessed.
These findings support continued dose development, but a low discontinuation rate in 48 patients cannot establish that uncommon or delayed toxicity has been excluded. Exposure duration also varies across participants. Longer follow-up and combination studies will be needed to determine whether 900 mg maintains an acceptable profile during broader treatment.
What did VS-7375 demonstrate in lung and colorectal cancer?
The first multicancer update included encouraging results beyond pancreatic cancer. In non-small cell lung cancer, 10 of 23 previously treated patients receiving VS-7375 at 600 mg daily achieved confirmed objective responses. The resulting rate was approximately 43%, with median follow-up of 4.4 months.
The company also reported a six-month landmark progression-free survival rate of 72% in that lung cancer cohort. Seventeen of the 23 patients remained on treatment at the October data cutoff. These findings support continued development but remain preliminary because the patient population was small and uncontrolled.
Another first-line lung cancer cohort evaluated VS-7375 at 600 mg in combination with standard chemotherapy and immunotherapy, or with pembrolizumab. Six of eight patients achieved an objective response, producing a preliminary 75% rate. The small sample size and use of additional active treatments prevent attribution of the entire response to VS-7375.
In metastatic colorectal cancer, two of six heavily pretreated patients receiving 900 mg alongside anti-EGFR treatment achieved responses. One was confirmed and one remained unconfirmed. The resulting 33% preliminary response rate therefore should not be described as a 33% confirmed response rate.
The findings across three tumor types support the hypothesis that KRAS G12D inhibition could have applications beyond one malignancy. However, different cancers may vary in their dependence on the mutation and the signaling pathways that contribute to resistance. Each indication will require its own clinical evidence.
How will the planned pancreatic cancer Phase 3 trial test the treatment?
Verastem has reached agreement with the FDA concerning the design of its proposed first-line metastatic pancreatic cancer Phase 3 study, TARGET-D 301. The company intends to open the trial before the end of 2026. Design agreement is an important regulatory development step, but it does not establish that the medicine will meet the study endpoints or receive approval.
The planned trial has three treatment arms. One will evaluate VS-7375 at 900 mg daily with anti-EGFR therapy in a chemotherapy-free combination. A second will investigate VS-7375 alongside gemcitabine and nab-paclitaxel, while the control arm will use investigator-selected standard chemotherapy consisting of gemcitabine plus nab-paclitaxel or modified FOLFIRINOX.
Progression-free survival and objective response rate will serve as dual primary endpoints, with overall survival assessed as a secondary endpoint. This design should provide a stronger basis for evaluating the treatment’s contribution than the current nonrandomized dose-escalation findings. It will also test whether the drug can be combined with established therapies without unacceptable toxicity.
The first-line setting differs substantially from the previously treated population that produced the initial response estimates. Patients may have different disease characteristics and treatment sensitivity before receiving chemotherapy. Consequently, the current second-line response rate cannot be used as a forecast of first-line Phase 3 efficacy.
Verastem is also continuing TARGET-D 201, TARGET-D 202 and TARGET-D 203, which investigate selected pancreatic, lung and colorectal cancer settings. Results from these studies may clarify whether the treatment can support further registration-directed development across multiple indications.
How does GenFleet’s role affect Verastem’s international strategy?
VS-7375 originated through Verastem’s collaboration with GenFleet Therapeutics. The candidate is also known as GFH375 and is being developed separately by GenFleet in Greater China. Verastem exercised its license option in January 2025, obtaining development and commercialization rights outside mainland China, Hong Kong, Macau and Taiwan.
GenFleet has generated clinical experience with the molecule in Chinese patients, including pancreatic and lung cancer populations. Those findings helped inform international development and provided an early rationale for dose escalation. However, the United States and Chinese studies involve separate regulatory programmes and patient populations.
The licensing arrangement includes milestone and royalty obligations to GenFleet. Verastem’s annual report identifies potential payments associated with development, commercialization and sales milestones across its broader GenFleet collaboration. These obligations affect the economics of future product commercialization but do not determine whether VS-7375 will receive regulatory approval.
The cross-border development strategy may provide advantages through accumulated clinical experience. Nevertheless, differences in study design, prior therapy and patient selection must be considered when interpreting combined evidence. Regulatory authorities will assess the data relevant to their jurisdictions and proposed indications.
What does Verastem’s $250 million financing mean for the clinical programme?
On the same day as its VS-7375 update, Verastem announced the pricing of an underwritten offering involving 30,937,500 common shares at $8 per share and pre-funded warrants covering another 312,503 shares. The transaction was expected to generate approximately $250 million in gross proceeds, before underwriting fees and other expenses. The company’s regulatory filing estimated net proceeds of approximately $234.7 million.
The offering was expected to close on or about October 15, subject to customary conditions. Pricing the transaction does not by itself establish that every closing condition has been satisfied or that the proceeds have been received. The company intends to use the funds for development of VS-7375, working capital and other corporate requirements.
The financing would strengthen resources available for the planned Phase 3 programme and the company’s parallel Phase 2 investigations. However, issuing new equity also increases the number of shares outstanding, creating dilution for existing shareholders. The eventual financial benefit will depend on whether the capital supports successful clinical development and regulatory progress.
Verastem already markets the AVMAPKI FAKZYNJA CO-PACK combination for a defined ovarian cancer indication. The company therefore has commercial pharmaceutical experience, but VS-7375 represents a separate and potentially much larger development opportunity. Its future revenue cannot be determined from the initial response rates.
The October clinical data provide evidence of activity across several KRAS G12D-mutated cancers, with pancreatic cancer offering the clearest early signal at the selected dose. The confirmed responses, complete response observations and molecular findings collectively support further investigation. However, the datasets remain small and lack randomized comparators.
The planned first-line Phase 3 trial will be the principal test of whether VS-7375 can produce an advantage over established pancreatic cancer treatment. Until those results are available, the medicine remains an investigational targeted therapy with encouraging early human activity but no demonstrated survival benefit or regulatory approval.
